Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | SHMT2 | P34897 | 3/20 | 0.51 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | EIF4E | P06730 | 6/20 | 0.47 |
| ▸ | RHOC | P08134 | 1/20 | 0.47 |
| ▸ | RHOA | P61586 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13150451 | 0.88 | NOTUM (0.44) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL629896 | 0.86 | LMNA (0.65) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL628118 | 0.85 | LMNA (0.60) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL629099 | 0.82 | KDM4E (0.74) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10029565 | 0.81 | KDM4E (0.61) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5025486 | 0.80 | LMNA (0.72) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL629227 | 0.80 | EIF4E (0.53) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL629535 | 0.80 | LMNA (0.56) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4363742 | 0.79 | MAPT (0.63) | SMN1; SMN2ALDH1A1HPGDGAA | |
| Fenclozic Acid SCHEMBL27104 | 0.78 | LMNA (0.73) | LMNAKDM4ESMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459203-A | Compositions and methods for modulating retinol binding to retinol binding protein 4(RBP4) | IRM LLC | 2012-05-16 | — | — | CN | disclosed |
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| EP-2419412-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120741-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | RBP4, RBP1, FABP4 | LMNA 1913/4885KDM4E 751/4885SMN1; SMN2 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.